AxoGen (AXGN) Competitors

AxoGen (NASDAQ:AXGN) and Envista (NYSE:NVST) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk.

Is AXGN or NVST more profitable?

AxoGen has a net margin of -7.91% compared to Envista's net margin of -44.56%. Envista's return on equity of 3.86% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-7.91%	-14.91%	-7.49%
Envista	-44.56%	3.86%	2.21%

Do analysts prefer AXGN or NVST?

AxoGen currently has a consensus price target of $22.60, indicating a potential upside of 31.93%. Envista has a consensus price target of $20.38, indicating a potential upside of 20.12%. Given AxoGen's stronger consensus rating and higher probable upside, equities analysts clearly believe AxoGen is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Envista	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.14

Does the media prefer AXGN or NVST?

In the previous week, Envista had 14 more articles in the media than AxoGen. MarketBeat recorded 20 mentions for Envista and 6 mentions for AxoGen. AxoGen's average media sentiment score of 1.52 beat Envista's score of 0.40 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Envista	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders and institutionals believe in AXGN or NVST?

80.3% of AxoGen shares are held by institutional investors. 7.0% of AxoGen shares are held by insiders. Comparatively, 1.3% of Envista shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community believe in AXGN or NVST?

AxoGen received 422 more outperform votes than Envista when rated by MarketBeat users. Likewise, 72.89% of users gave AxoGen an outperform vote while only 33.33% of users gave Envista an outperform vote.

Company	Underperform	Outperform
AxoGen	Outperform Votes 457 72.89%	Underperform Votes 170 27.11%
Envista	Outperform Votes 35 33.33%	Underperform Votes 70 66.67%

Which has more volatility & risk, AXGN or NVST?

AxoGen has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Envista has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.

Which has higher valuation and earnings, AXGN or NVST?

AxoGen has higher earnings, but lower revenue than Envista. AxoGen is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$187.34M	4.05	-$21.72M	-$0.22	-77.86
Envista	$2.51B	1.15	-$1.12B	-$6.49	-2.61

Summary

AxoGen beats Envista on 13 of the 18 factors compared between the two stocks.